Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/6/2025 | $202.00 | Hold → Buy | Stifel |
| 9/25/2025 | $190.00 | Buy | Jefferies |
| 7/21/2025 | $142.00 | Hold | Truist |
| 4/28/2025 | $118.00 | Buy → Hold | HSBC Securities |
| 4/4/2025 | Buy → Hold | Argus | |
| 2/11/2025 | $160.00 | Mkt Perform | Bernstein |
| 1/2/2025 | $315.00 → $138.00 | Overweight → Neutral | Piper Sandler |
| 12/20/2024 | $230.00 → $164.00 | Outperform → Market Perform | BMO Capital Markets |
4 - BIOGEN INC. (0000875045) (Issuer)
4 - BIOGEN INC. (0000875045) (Issuer)
4 - BIOGEN INC. (0000875045) (Issuer)
– Despite treatment with standard-of-care anti-seizure medicines, children with Dravet syndrome experienced high seizure burden and plateaued in neurodevelopment, resulting in a widening gap relative to children with typical development – – Findings underscore the urgent need for new medicines that target the underlying genetic cause of Dravet syndrome to improve long-term outcomes – Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, and Biogen Inc. (NASDAQ:BIIB) today announced the publication of final data from the BUTTERFLY study, a prospective, two-year natural history study
– Despite treatment with standard-of-care anti-seizure medicines, children with Dravet syndrome experienced high seizure burden and plateaued in neurodevelopment, resulting in a widening gap relative to children with typical development – – Findings underscore the urgent need for new medicines that target the underlying genetic cause of Dravet syndrome to improve long-term outcomes – CAMBRIDGE, Mass. and BEDFORD, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) and Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced the publication of final data fr
Positive CHMP opinion is based on data from the DEVOTE study which evaluated the high dose regimen of nusinersen in treatment-naive participants and those transitioning from the currently approved 12mg dose regimen1Final European Commission decision expected in January 2026SMA is a rare, genetic, neuromuscular disease that affects individuals of all ages2 CAMBRIDGE, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending by consensus the approval of the high dose regimen of nusinersen for the treatment of 5q spinal muscular a
Stifel upgraded Biogen from Hold to Buy and set a new price target of $202.00
Jefferies initiated coverage of Biogen with a rating of Buy and set a new price target of $190.00
Truist resumed coverage of Biogen with a rating of Hold and set a new price target of $142.00
Submission status for BIOGEN INC's drug VUMERITY (ORIG-1) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/12/2024. Application Category: NDA, Application Number: 761347, Application Classification: Type 3 - New Dosage Form
Submission status for BIOGEN INC's drug VUMERITY (SUPPL-17) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/11/2024. Application Category: NDA, Application Number: 211855, Application Classification: Manufacturing (CMC)
Submission status for BIOGEN INC's drug VUMERITY (SUPPL-15) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211855, Application Classification: Labeling
SCHEDULE 13G/A - BIOGEN INC. (0000875045) (Subject)
SCHEDULE 13G - BIOGEN INC. (0000875045) (Subject)
10-Q - BIOGEN INC. (0000875045) (Filer)
4 - BIOGEN INC. (0000875045) (Issuer)
4 - BIOGEN INC. (0000875045) (Issuer)
In the news release, Global Leaders Jesús Mantas and Wes Bricker Join NACD Board of Directors, issued 10-Oct-2025 by National Association of Corporate Directors over PR Newswire, we are advised by the company that the third paragraph, the end of the last line, should read "IBM Business Transformation Services" instead of "IBM Consulting Business Transformation Services" as originally issued inadvertently. The complete, corrected release follows: Global Leaders Jesús Mantas and Wes Bricker Join NACD Board of Directors Seasoned executives bring deep expertise in innovation, governance, and business to strengthen NACD's leadership board excellence WASHINGTON, Oct. 10, 2025 /PRNewswire/ -- Th
Seasoned executives bring deep expertise in innovation, governance, and business to strengthen NACD's leadership board excellence WASHINGTON, Oct. 10, 2025 /PRNewswire/ -- The National Association of Corporate Directors® (NACD®) today announced the appointment of Jesús Mantas, recently retired Global Leader of IBM Business Consulting, and Wes Bricker, Global Assurance Leader at PwC, to its board of directors, effective immediately. The appointments bring to NACD a wealth of experience spanning technology, innovation, assurance, governance and capital markets — further strengthening the association's ability to guide directors as they navigate today's rapidly evolving business landscape. Mant
BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors. "We are pleased to have Dr. Radhakrishnan join the Board at this time of tremendous clinical momentum at Entrada, led by the continued advancement of our Duchenne muscular dystrophy franchise. Dr. Radhakrishnan's deep and meaningful experience in global drug development will be invaluable as we quickly advance our novel Duchenne programs into multiple patient-focused clinical trials throughout this year," said Dipal Doshi, Chief Executive Officer at Entrada Therapeutics. "I'm honored to join the Board of Entrada
SC 13G/A - BIOGEN INC. (0000875045) (Subject)
SC 13G/A - BIOGEN INC. (0000875045) (Subject)
SC 13G - BIOGEN INC. (0000875045) (Subject)
CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) has completed the acquisition of Alcyone Therapeutics, a clinical-stage biotechnology company known for its innovative CNS therapy delivery solutions, such as the ThecaFlex DRx™ drug delivery system. ThecaFlex DRx™ is an investigational implantable device designed to provide an alternative to repeat lumbar punctures in chronic intrathecal administration of medicines, which could ease both patient experience and accessibility for a broader population of people living with neurologic disorders. ThecaFlex DRx™ has been in development since 2019, with the PIERRE and PIERRE-PK clinical studies for nusinersen curren
Dapirolizumab pegol (DZP) Phase 3 study presentations in SLE to show efficacy results across multiple clinical endpoints, including low disease activity/remission, flares, fatigue, joint pain and quality of lifePresentation of preclinical study of DZP showing minimal to no human placental transfer CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) today announced upcoming presentations from studies evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L drug candidate, in systemic lupus erythematosus (SLE) to be presented at the American College of Rheumatology (ACR) Convergence 2025 (October 24-29) in Chicago, Illinois. The presentations will show effi
Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy (SMA)Interim Phase 1 data show children with SMA previously treated with gene therapy experienced a substantial slowing of neurodegeneration and clinically meaningful improvements in motor function following initiation of salanersenBased on these encouraging Phase 1 data, Biogen is engaging with regulators to advance salanersen to registrational stage studies, building on extensive experience in SMA CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) announced topline results from the Phase 1 study of